Relmada Therapeutics, Inc.

NASDAQ:RLMD

Biotechnology

Healthcare
$2.86 -0.97%

-$0.06 today

Market cap
$304.61M
Beta
0.39
P/E (TTM)
-9.6
EPS (TTM)
-$0.68
52W Low $0.52High $8.00

Volume 1.86M

Average 1.24M

RLMD Other Working Capital

Cash effect of changes in other operating assets and liabilities.

Relmada Therapeutics, Inc.NASDAQ: RLMD

Other Working Capital · Q1 FY2026 · quarter ended Mar 2026

Other working capital grows, but more slowly than its trailing trend

Q1 FY2026 other working capital of $1.96M (cash outflow) rose 3.0% year over year, behind the +222.5% change in trailing-twelve-month other working capital.

Context

  • Other working capital increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +3.0% toward the trailing-twelve-month pace of +222.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.96M-275.5% QoQ
Last fiscal yearDec 2025
-$1.39M-37.1% YoY
LTMMar 2026
$3.71M+222.5% YoY
Other Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.0%——
1 year-37.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Working Capital history

USD · from the cash flow

Latest · FY2025
(1.39M) USD
Year-over-year change
+37.1%

Other Working Capital vs competitors

How RLMD compares with its peers on the latest reported figures

  • RLMD's LTM Mar 2026 other working capital of $3.71M is the 3rd largest of the 9 companies compared; the peer median is $371.5K.
  • Its year-over-year change of +222.5% is the 2nd highest of 9, against a peer median of +26.9%.
RLMD Competitors Peer median
Other Working Capital for RLMD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TCRXTScan Therapeutics, Inc.LTM Mar 2026$8.16M +273.8%+12.1%89.3%
IMUXImmunic, Inc.LTM Mar 2026$6.51M -4.9%-59.0%—
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$3.71M +222.5%——
VXRTVaxart, Inc.LTM Mar 2026$2.06M +58.6%+2.8%0.8%
CBUSCibus, Inc.LTM Mar 2026$2.04M -145.3%—47.5%
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$1.75M +147.5%——
ACETAdicet Bio, Inc.LTM Mar 2026$724K +183.7%-19.4%—
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$593K -165.7%+45.5%—
FBIOFortress Biotech, Inc.LTM Mar 2026$150K -105.8%-24.2%0.2%
Peer median (excluding RLMD) $371.5K+26.9%-8.3%24.2%

Competitors are the stored peer set for RLMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(125.75M)(157.04M)(98.79M)(79.98M)(57.39M)
Depreciation & Amortization1.26K0000
Deferred Income Tax00000
Stock-Based Compensation40.49M44.19M43.81M30.19M14.96M
Change in Working Capital(7.86M)10.59M3.08M(1.58M)(3.95M)
Accounts Receivables79.46K(426.06K)512.43K00
Inventory00000
Accounts Payables2.85M421.04K(1.76M)624.55K(2.56M)
Other Working Capital(10.79M)10.6M4.32M(2.21M)(1.39M)
Other Non-Cash Items1.25M(1.55M)241.16K(381.66K)586.18K
Operating Cash Flow(91.87M)(103.8M)(51.66M)(51.76M)(45.79M)
Capital Expenditures00(4)00
Acquisitions (Net)00000
Purchases of Investments(222.98M)(47.29M)(90.46M)(12.08M)(83.83M)
Sales of Investments168.86M67.03M140.92M63.64M35.69M
Other Investing Activities00000
Investing Cash Flow(54.12M)19.73M50.45M51.56M(48.14M)
Debt Repayment00000
Common Stock Issued185.31M42.73M0246.75K93.64M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.63M2.29M(98.46K)(287.09K)(73.02K)
Financing Cash Flow187.94M45.02M(98.46K)(40.34K)93.56M
Effect of Forex Changes00000
Net Change in Cash41.95M(39.05M)(1.3M)(234.54K)(360.49K)
Free Cash Flow(91.87M)(103.8M)(51.66M)(51.76M)(45.79M)

Relmada Therapeutics, Inc.

NASDAQ:RLMD

Intrinsic Alpha fair value

Locked

Current Price

$2.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.